- NEWS FEATURE
How ecstasy and psilocybin are shaking up psychiatry
Illustration by Gizem Vural
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
24,99 € / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
204,58 € per year
only 4,01 € per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 589, 506-509 (2021)
doi: https://doi.org/10.1038/d41586-021-00187-9
References
Davis, A. K. et al. JAMA Psychiatry http://doi.org/10.1001/jamapsychiatry.2020.3285 (2020).
Agin-Liebes, G. I. et al. J. Psychopharmacol. 34, 155–166 (2020).
Carhart-Harris, R. L. et al. Psychopharmacology 235, 399–408 (2018).
Vollenweider, F. X. & Preller, K. H. Nature Rev. Neurosci. 21, 611–624 (2020).
Vollenweider, F. X. et al. Neuropsychopharmacology 16, 357–372 (1997).
Zhang, G. et al. Neuropharmacology 64, 403–413 (2013).
Hutten, N. R. P. W. et al. ACS Pharmacol. Transl. Sci. https://doi.org/10.1021/acsptsci.0c00099 (2020).
Lebedev, A. V. et al. Hum. Brain Mapp. 37, 3203–3213 (2016).
Psychedelics move from agents of rebellion towards therapeutics
Antidepressant based on party drug gets backing from FDA advisory group
Psychedelic compound in ecstasy moves closer to approval to treat PTSD
First look at LSD in action reveals acid-trip biochemistry
Magic-mushroom drug lifts depression in first human trial